CTIS2022-501661-47-00招募中1 期
INCB 39110-801 A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib (INCB039110) - INCB 39110-801
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Incyte Corp.
- 入组人数
- 14
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Currently enrolled and receiving treatment in an Incyte-sponsored itacitinib (INCB 39110)-based clinical study (parent protocol)., Currently tolerating treatment as defined by the parent protocol., Currently receiving clinical benefit from itacitinib-based treatment, as determined by the investigator., Has demonstrated compliance, as assessed by the investigator, with the parent protocol requirements., Willingness and ability to comply with scheduled visits, treatment plans, and any other study procedures indicated in this Protocol., Willingness to avoid pregnancy or fathering children based on criteria in Section 5. l ., Ability to comprehend and willingness to sign an ICF.
排除标准
- •Able to access itacitinib therapy commercially., Participants with an uncontrolled intercurrent illness or any concurrent condition that, in the investigator's opinion, would jeopardize the safety of the participant or compliance with the Protocol., Pregnant or breastfeeding women., Any personal status that would prohibit clinical trial participation under local regulations.
研究者
相似试验
招募中
1 期
A Phase 1b/2 Study of PF-07220060 in Combination with PF-07104091 Plus Endocrine Therapy in Participants with BC and other Advanced Solid TumorsCTIS2023-509504-15-00Pfizer Inc.240
招募中
1 期
A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Parsaclisib (INCB050465)Advanced malignancies and IAI diseasesMedDRA version: 21.0Level: LLTClassification code: 10048683Term: Advanced cancer Class: 10029104MedDRA version: 20.0Level: LLTClassification code: 10003825Term: Autoimmune hemolytic anemia Class: 10005329CTIS2022-501687-18-00Incyte Corp.177
已完成
2 期
INCB 54828-201 A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (FIGHT-201)urothelial carcinoma10038364bladder cancerNL-OMON49349Incyte Corporation7
进行中（未招募）
1 期
Open-Labeled Study of Dabrafenib plus Trametinib in Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the Brain.Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the BrainMedDRA version: 19.1Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 100000004864EUCTR2013-003452-21-DEovartis Pharma Services AG120
进行中（未招募）
1 期
BRF117277: A Phase II, Open-Label, Multicentre Study of Dabrafenib plus Trametinib in Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the BrainEUCTR2013-003452-21-ITGlaxoSmithKline Research & Development Ltd125